Plain-English translation of NCT07030894 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This study is testing a combination of two medications — budesonide and ambrisentan — to treat IgA nephropathy, a kidney disease where the body's immune system damages the kidneys and causes protein to leak into the urine. Researchers want to see if taking both medications together for nine months can slow kidney damage and reduce protein loss in patients with this condition.
IgA nephropathy is a serious kidney disease that can lead to kidney failure over time, and current treatments don't work well enough for all patients. This trial is testing whether this medication combination might be a better option to protect the kidneys and prevent further damage.
You likely qualify if…
You likely don't qualify if…
If you join, you'll take two oral medications every day for nine weeks: one dose of budesonide and one dose of ambrisentan. You'll have about six clinic visits over that time for blood tests, urine tests, and check-ins to make sure the treatment is working and safe. The whole trial lasts about nine months from start to finish.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China
Phase
Post-approval monitoring
Sponsor
The First Hospital of Jilin University
Enrollment target
~129 participants
Started
September 2025
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Weixia Sun
The First Hospital of Jilin University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.